Anthropic's life sciences team is partnering with biotech firms to accelerate drug development using Claude AI. Over recent months, the scientists have engaged in deep research partnerships with six organizations: Big Hat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group. Anthropic has also begun its own drug discovery efforts, including programs for rare childhood forms of muscular dystrophy.
The strategy involves increasing AI involvement across the entire drug development process, from target identification and molecule design to regulatory filings and clinical trial administration. Rather than solving a single problem, Anthropic focuses on distributed bottlenecks throughout the process. The company plans to scale this work substantially, using real-world programs to identify strengths and limitations of their models.
These partnerships serve three goals: understanding model capabilities, serving as case studies for the wider life sciences community, and potentially resulting in effective new medicines. Case studies include Generate Biomedicines reengineering CAR T-cell therapy for solid tumors, where Claude Code proposals created designs roughly 70% shorter and more effective in lab tests. Divergence Labs is working on a novel food allergy treatment targeting IgE molecules.
These projects aim to increase the rate of new cures by integrating Claude deeper into biotechnology firm processes.
Source: Hacker News · Summarized by HeadlinesBriefing